CMPX

Announcements

Nothing here yet

Daily updates

• Compass Therapeutics reported FDA feedback requiring an additional study demonstrating an overall survival benefit before a BLA filing for tovecimig in pretreated biliary tract cancer, creating a regulatory delay despite favorable Phase 2/3 ORR and PFS results.Sep 22, 2026

FDA designations

Nothing here yet

News

• Compass Therapeutics provides a regulatory update on tovecimig in biliary tract cancer following FDA feedbackSep 22, 2026
• Tovecimig showed statistically significant benefit in the COMPANION-002 Phase 2/3 study for biliary tract cancer patientsApr 27, 2026